Biotech News

ImmunityBio Named No. 2 Fastest-Growing Technology Company in North America on the 2026 Deloitte Technology Fast 500™

ImmunityBio (IBRX)ImmunityBioCommercial

Ranking reflects significant revenue growth over last three years and continued global expansion of ANKTIVA ®, now authorized in 35 countries CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 19, 2026-- ImmunityBio, Inc. ( NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that it

Related news

IBRXImmunityBio2026-11-11 02:31 EST

ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026

IBRXImmunityBio2026-11-04 13:00 EST

ImmunityBio Announces First Patients in Europe Treated with ANKTIVA® Plus BCG for BCG-unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ

SNDXSyndax Pharmaceuticals2026-10-15 20:01 EST

Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List

SNDXSyndax Pharmaceuticals2026-11-04 21:01 EST

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

RVMDRevolution Medicines2026-10-27 20:05 EST

Revolution Medicines to Participate in November 2026 Investor Conferences

SNYSanofi2026-11-12 17:30 EST

Sanofi: Information concerning the total number of voting rights and shares - October 2026

SNYSanofi2026-10-12 16:05 EST

Sanofi: Information concerning the total number of voting rights and shares – September 2026

NRIXNurix Therapeutics2026-11-05 12:00 EST

Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition

BNTXBioNTech2026-10-26 09:00 EST

BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer

REPLReplimune Group2026-10-22 12:00 EST

Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026

ImmunityBio

Immune-Based Cancer Therapies ImmunityBio develops therapies that activate innate and adaptive immune responses against cancer. Its platform combines cytokine biology, cell therapy and immunotherapy combinations. ANKTIVA ANKTIVA is an IL-15 superagonist approved with BCG for selected patients with BCG-unresponsive non-muscle-invasive...

Recent company news

Stock data

Close
6.57 USD
Market cap
7.57B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States